Abstract

Aptamers, a group of nucleic acids which can specifically bind to a target molecule, have drawn extensive interest over the past few decades. For analytics, aptamers represent a viable alternative to gold-standard antibodies due to their oligonucleic nature combined with advantageous properties, including higher stability in harsh environments and longer shelf-life. Indeed, over the last decade, aptamers have been used in numerous bioanalytical assays and in various point-of-care testing (POCT) platforms. The latter allows for rapid on-site testing and can be performed outside a laboratory by unskilled labor. Aptamer technology for POCT is not limited just to medical diagnostics; it can be used for a range of applications, including environmental monitoring and quality control. In this review, we critically examine the use of aptamers in POCT with an emphasis on their advantages and limitations. We also examine the recent success of aptasensor technology and how these findings pave the way for the analysis of small molecules in POCT and other health-related applications. Finally, the current major limitations of aptamers are discussed, and possible approaches for overcoming these challenges are presented.

Highlights

  • Aptamers, which are short nucleic acid sequences, were described in 1990 for the first time and proposed to be a promising alternative to antibodies [1,2]

  • A small percentage of the library’s sequences binds to the target and subsequently separates. The latter are several stringent selection process, aptamers offer a feasible alternative to antibodies and they offer amplified via polymerase chain reaction (PCR) and the selection process is typically repeated for 8–15 prominent advantages

  • In point-of-care testing, aptamers offer a wide range of advantages compared to antibodies when used as the biosensing platform

Read more

Summary

Introduction

Aptamers, which are short nucleic acid sequences, were described in 1990 for the first time and proposed to be a promising alternative to antibodies [1,2]. Aptamers were extensively tested and established in a variety of applications. After all these years, only a handful of aptamers are commercially used (and approved) in diagnostics and therapeutics. As for the latter, the most prominent therapeutic aptamer is Macugen by Pfizer, which was approved by the FDA in. Aptamers are widely developed and successfully applied for numerous diagnostic applications and yet their translation into commercial use in general and point-of-care testing (POCT) is still in its infancy. We highlight the challenges in the use of aptamers for diagnostics in general and POCT applications.

Small Molecule Targets
Biosensors
Aptasensors
Sandwich or Sandwich-Like Mode
Integration of Nanomaterials
Working
Comparison of Aptasensors and Immunosensors for Small Molecule Sensing
Challenges in the Detection of Small Molecules Using Aptasensors
General Challenges
SELEX-Related Challenges
Challenges regarding Kd Determination
Conclusion and Future Prospects
Conclusions and Future Prospects

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.